Тематические порталы ИД "Русский врач": Кардиология, Педиатрия



Ингибиторы ангиотензинпревращающего фермента при инфаркте миокарда: итоги исследовательского проекта SMILE



Ингибиторы ангиотензинпревращающего фермента при инфаркте миокарда: итоги исследовательского проекта SMILE

Многолетний научный проект SMILE с использованием зофеноприла продемонстрировал целесообразность и безопасность раннего назначения препарата у гемодинамически стабильных больных с передним инфарктом миокарда без тромболитической терапии, а также представил свидетельства клинического значения особенностей отдельных ингибиторов ангиотензинпревращающего фермента, связанных с их химикофармакологическими свойствами.
Angiotensin-converting enzyme inhibitors in myocardial infarction: results of the smile study project
The long-term SMILE study project using zofenopril has demonstrated that it is expedient and safe to early use the drug in hemodynamically stable patients with anterior myocardial infarction receiving no thrombolytic therapy and provided evidence that the specific features of individual angiotensin-converting enzyme inhibitors, which are associated with their chemicopharmacological properties, are of clinical value.
  1. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction // Circulation. – 1998; 97: 2202–12.
  2. Ambrosioni E., Borghi C., Magnani В. For the survival of myocardial infarction long term evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor on mortality and morbidity after anterior myocardial infarction // N. Engl. J. Med. – 1995; 332: 80–5.
  3. Al-Khadra A., Salem D., Rand W. et al. Antiplatelet agents and survival: a cohort analysis from studies of left ventricular dysfunction (SOLVD) trial // JАСС. – 1998; 31: 419–25.
  4. Borghi C. Cardioprotective role of ace-i in patients with acute MI: THE SMILE -OVERALL PROJECT // JACC. – 2012; 59 (13): 454.
  5. Borghi C., Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study // Am. Heart. J. – 2003; 145 (1): 80–7.
  6. Borghi C., Ambrosioni E. Оn behalf of the SMILE Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE) ISCHEMIA study // Am. Heart. J. – 2007; 153: 445, e7–445, e 14.
  7. Borghi C., Ambrosioni E., Bacchelli S., Vinereanu D. Double-blind, randomized comparison between zofenopril and ramipril in patients with LV dysfunction treated with ASA: the SMILE IV study // Eur. Heart. J. – 2011; 32 (Abstr. Suppl.): 967.
  8. Borghi C., Bacchelli S., Esposti D. et al. On behalf of the SMILE Study Investigators. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension // Am. J. Hypertens. – 1999; 12 (7): 665–72.
  9. Borghi C., Bacchelli S., Esposti D. et al. Effects of the Early ACE-Inhibition in Diabetic Nonthrombolyzed Patients With Anterior Acute Myocardial Infarction // Diabetes Care. – 2003; 26 (6): 1862–8.
  10. Borghi C., Bacchelli S., Esposti D. et al. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin–converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction // Am. Heart. J. – 2006; 152 (3): 470–7.
  11. Borghi C., Cosentino E.R., Esposti D.D. SMILE IV Investigators. Double-blind, randomized comparison of zofenopril and rampril in patients with post-MI left ventricular dysfunction treated with ASA: the SMILE IV study // JACC. – 2011; 57 (17): 300.
  12. Bosch J., Lonn E., Pogue J. et al. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension // Circulation. – 2005; 112 (9): 1339–46.
  13. Buikema H., Monnink S., Tio R. et al. Comparison of zofenopril and lisinopril to study the role of the sulfhydrylgroup in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure // Br. J. Pharmacol. – 2000; 130 (8): 1999–2007.
  14. Cacciatore F., Bruzzese G., Vitale D.F. et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients// Eur. J. Clin. Pharmacol. – 2011; 67 (9): 877–83.
  15. Chopra M., Beswick H., Clapperton M. et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE-inhibitors // J. Cardiovasc. Pharmacol. – 1992; 19: 330–40.
  16. Cushman D., Wang F., Fung W. et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE) // Br. J. Clin. Pharmacol. – 1989; 2: 115–30.
  17. De Nigris F. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduces susceptibility of plasma LDL to «in vitro» oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice // Int. J. Cardiol. – 2001; 81 (2–3): 107–15.
  18. Desideri G., Grassi D., Croce G. et al. Different Effects of Angiotensin Converting Enzyme Inhibitors on Endothelin-1 and Nitric Oxide Balance in Human Vascular Endothelial Cells: Evidence of an Oxidant-Sensitive Pathway //Mediators of Inflammation. – 2008; 2008: Article ID 305087. doi:10.1155/2008/305087.
  19. Dzau V. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis // Hypertension. – 2001; 37 (4): 1047–52.
  20. Evangelista S., Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensinconverting enzyme inhibitor Zofenopril // J. Int. Med. Res. – 2005; 33 (1): 42–54.
  21. Flather M., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in heart failure or left-ventricular dysfunction: a systemic overview of data from individual patients // Lancet. – 2000; 355: 1575–81.
  22. Frascarelli S., Ghelardoni S., Ronca-Testoni S. et al. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion // J. Cardiovasc. Pharmacol. – 2004; 43: 294–9.
  23. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure // JАСС. – 1992; 20 (7): 1549–55.
  24. Kober L., Torp-Pedersen C., Carlsen J. et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction // New. Engl. J. Med. – 1995; 333: 1670–6.
  25. Latini R., Maggioni A., Flather M. et al. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials // Circulation. – 1995; 92: 3132–7.
  26. Latini R., Tognoni G., Maggioni A.P. et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and assence of aspirin // JАСС. – 2000;35:1801–7.
  27. López-Sendón J., Swedberg K., McMurray J. et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology // Eur. Heart J. – 2004; 25: 1454–70.
  28. Napoli C., Bruzzese G., Ignarro L. et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension // Am. Heart. J. – 2008; 156 (6): 1154, e1–8.
  29. Napoli C., Sica V., de Nigris F. et al. Sulfhydryl angiotensin-converting enzymeinhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension // Am. Heart. J. – 2004; 148: e5.
  30. Nguyen Kh., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the cooperative new Scandinavian enalapril Survival study II (CONSENSUS II) // Am. J. Cardiol. – 1997; 79: 115–9.
  31. Peterson J., Topol E., Sapp S. et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease // Am. J. Med. – 2000; 109: 371–7.
  32. Omland T., Aarsland T., Aakvaag A. et al. The effect of early converting enzyme inhibition on neurahumorol activation in acute myocardiol infarction // lnt. J. Cardiol. – 1993; 42: 37–45.
  33. Pfeffer M., Braunwald E., Moye L. et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial // New Engl. J. Med. – 1992; 327 (10): 669–77.
  34. Teo K., Yusuf S., Pfeffer M. et al. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review // Lancet. – 2002; 360: 1037–42.
  35. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure // Lancet. – 1993; 342: 821–8.
  36. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindоpril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. – 2003; 362: 782–8.
  37. Walsh J., Botin P., Howkins M. et al. Ventricular dilatation in the absence of ACE inhibitors: inHuence of haernadynamic and neurohormonal variables following myocardial infarction // Heart. – 1999; 81: 33–9.


→ Фармакопейные статьи

→ Медицинские архивы на службе современного врача

→ Перечень медицинских технологий

ЭКД архив


Информационные партнеры: